Released Nov 3, 2026, after the close
10-Q filed Nov 3, 2026, 34 days after period end · 0001759425-26-000062
Received U.S. FDA approval of and launched ATEBRIOZ ® (zilurgisertib) to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $185.72M | $133.01M | $90.38M | $47.73M |
| Net Income | -$40.77M | $2.91M |
Mirum Pharmaceuticals, Inc. · CIK 1759425 · Engraved from SEC EDGAR
| -$14.24M |
| -$23.59M |
| EPS Diluted | -$0.87 | $0.05 | -$0.30 | -$0.57 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Total revenue for the quarter ended September 30, 2026 was $185.7 million compared to $133.0 million for the quarter ended September 30, 2025.¶2
Total operating expenses were $245.5 million for the quarter ended September 30, 2026 compared to $130.4 million for the quarter ended September 30, 2025.¶3
Mirum raised its 2026 net product sales guidance to $715 million to $720 million.¶4¶5
Mirum repurchased $20.0 million aggregate principal amount of its 4.00% convertible senior subordinated notes due 2029, which represented approximately 25% of the outstanding notes.¶6
Unrestricted cash, cash equivalents, and investments were $500.5 million as of September 30, 2026, compared to $391.4 million as of December 31, 2025.¶7